General
Preferred name
MOXISYLYTE
Synonyms
MOXISYLYTE HYDROCHLORIDE ()
Moxisylytum ()
thymoxamine hydrochloride ()
Moxisylyte hydrochoride ()
Moxisylyte (hydrochloride) ()
Moxisylyte HCl ()
Acetoxythymoxamine ()
Moxivig ()
NSC-170448 ()
Thymoxamine ()
Carlytene ()
Erecnos ()
Thymoxamine hcl ()
P&D ID
PD009005
CAS
54-32-0
964-52-3
Tags
natural product
drug
available
Drug Status
investigational
approved
withdrawn
Drug indication
Erectile dysfunction
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Moxisylyte is an antagonist of α1 adrenoceptors, with some selectivity for the α1A subtype . It improves blood circulation to the extremities and has been used to treat primary Raynaud's syndrome .
(GtoPdb)
INDICATION
By the WHO, moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhage.[T91] The cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolus.[A31644] ; ; On the other hand, the FDA classified moxisylyte for the reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma.[L1172] Closed-angle glaucoma is caused by the contact between the iris and the trabecular meshwork. This contact will damage the aqueous outflow by the meshwork thus, increasing eye pressure and producing the symptoms of glaucoma.[A31645] Mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closed-angle glaucoma.This risk is explained by the generation of a pupillary block, which is the contact between the pupillary margins and the lens, thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradient.[L1173] ; ; Moxisylyte is also approved in France as the first drug for the treatment of impotence.[A31647]
DESCRIPTION
alpha1-Adrenoceptor antagonist
(LOPAC library)
DESCRIPTION
Moxisylyte hydrochloride is alpha 1-adrenoceptor antagonist. It can vasodilates cerebral vessels without reducing blood pressure. It is used as peripheral vasodilator. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine. It is used as sympathomimetic agents. It has been listed.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
22
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
279.18
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
1
Aromatic Ring Count
1
cLogP
2.98
TPSA
38.77
Fraction CSP3
0.56
Chiral centers
0.0
Largest ring
6.0
QED
0.59
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
alpha1
Pathway
Neuroscience
GPCR/G protein
Neuronal Signaling
Target
Adrenergic Receptor
MOA
Adrenergic Receptor antagonist
ATC
C04AX10
G04BE06
Toxicity type
hepatic
Solubility
Soluble in ethanol (50 mg/ml)
Source data
